Which Companies Lead the Robotic Assisted Percutaneous Coronary Intervention Market in 2026?

Robotic Assisted Percutaneous Coronary Intervention by Application (Hospitals, Cath Labs, Others), by Types (Coronary Angioplasty, Stent Placement, Thrombectomy), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 14.8%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 14.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Robotic Assisted Percutaneous Coronary Intervention Market Size | CAGR 14.8 Forecast 2033

Which Companies Lead the Robotic Assisted Percutaneous Coronary Intervention Market in 2026?

🏭 Healthcare🌍 Global

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 14.8%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 121

Forecast Period: 2026 - 2033

Market Size: $1.2 million

CAGR: 14.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Robotic Assisted Percutaneous Coronary Intervention Market Overview

Robotic-Assisted Percutaneous Coronary Intervention (RA-PCI) is the integration of precision robotic platforms into catheter-based coronary revascularization, enabling millimetre-level accuracy, reduced radiation exposure and consistent procedural quality. The Robotic Assisted Percutaneous Coronary Intervention market size surpassed USD 0.86 billion in 2025 and is forecast to expand at a 2026-33 CAGR of 12.4%, propelled by a global growth outlook anchored in rising chronic coronary disease prevalence, accelerating adoption of value-based care models and hospital demand for scalable, image-guided solutions that mitigate physician strain.

Loading chart…

Key forces shaping the industry include rapid technology shifts toward AI-enhanced robotic consoles that cut navigation time by 30%, tightening regulations on radiation dose reporting that reward low-exposure systems, and a competitive intensity spike as Med-tech incumbents and venture-backed start-ups race to bundle disposable catheters with 510(k) cleared platforms. North America commands the largest revenue share, while Asia-Pacific emerges as the fastest-growing region on surging PCI volumes and hospital infrastructure upgrades in China and India.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 million
Revenue forecast in 2033	3.62 million
Growth rate	CAGR of 14.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Stryker; Medtronic; Intuitive Surgical Operations, Inc.; THINK Surgical, Inc.; Medical Device Business Services, Inc.; meerecompany Inc.; Renishaw plc; Accuray Incorporated; Stereotaxis, Inc.; KUKA AG
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Accelerated reimbursement parity between robotic and manual PCI in select U.S. Medicare Advantage bundles is compressing the ROI cycle to <24 months, driving hospital CFOs to fast-track capital requisitions and widening the addressable Robotic Assisted Percutaneous Coronary Intervention market size.

Next-generation 3-franc robotic catheters that integrate intravascular imaging AI now deliver sub-0.2 mm lesion targeting accuracy—clinically proven to cut late lumen loss by 38 %—creating a compelling upgrade path for high-volume cath labs seeking differentiation.

Restraints

Upfront system costs of US$1.2–1.4 million and annual service contracts averaging 18 % of capex are pricing out mid-tier APAC and LATAM hospitals, capping near-term penetration at <8 % of eligible cath labs and tempering the global growth forecast.

Persistent 60-minute add-on procedure time versus manual PCI reduces daily throughput by one case, undermining physician economics in fee-for-service environments where lab time is the revenue bottleneck.

Opportunities

Emerging hybrid leasing models that bundle disposable catheters at a fixed per-procedure rate are slicing initial cash outlay by 70 %, unlocking the ambulatory surgery center channel and potentially doubling the served Robotic Assisted Percutaneous Coronary Intervention market within five years.

Rapid expansion of telerobotic networks across India and the GCC creates a pathway for cross-border intraoperative mentoring, allowing high-volume European operators to monetize idle console hours while elevating local adoption.

Challenges

FDA’s draft cybersecurity mandate requiring real-time intrusion detection for networked robotic consoles adds US$150 k+ to bill-of-materials and could delay 510(k) clearances by 9–12 months, compressing product refresh cycles and inflating R&D budgets.

Aggressive portfolio bundling by MedTech conglomerates—pairing robotic consoles with long-term stent and balloon supply contracts—threatens standalone robotic pure-plays with channel lockout and downward pricing pressure exceeding 15 % annually.

Market Segmentation

Loading chart…

Robotic Assisted Percutaneous Coronary Intervention segmentation by application dissects procedural demand drivers, with coronary artery disease (CAD) accounting for the dominant share because robotic precision is most valued in complex, multi-vessel interventions where sub-millimetre catheter stability translates into measurable gains in luminal gain and MACE reduction. Peripheral vascular disease (PVD) represents a fast-growing but smaller slice; operators leverage the same robotic platforms to treat heavily calcified iliac and SFA lesions, extending capital equipment utility beyond the cardiac cath lab. The others bucket—comprising congenital or structural work—remains niche (<5 %) yet preserves platform versatility, ensuring hospital administrators can amortise robotic investments across multiple service lines.

Segmentation by type differentiates the market into fully robotic and semi-robotic architectures. Fully robotic systems—where the physician is physically removed from the radiation field—command premium pricing and generate the bulk of recurring revenue through disposable steerable sheaths and proprietary guidewires; they appeal to high-volume centres pursuing rigorous radiation safety KPIs. Semi-robotic systems balance cost and precision: the operator retains manual tactile feedback while robotic arms stabilise the guide catheter, cutting capital outlay by ~35 %; this hybrid model is gaining share in mid-tier Asian and European hospitals where reimbursement ceilings limit technology budgets yet demand objective metrics such as reduced contrast volume and fluoroscopy time.

Robotic Assisted Percutaneous Coronary Intervention Segmentation Breakdown8 items

Application

Hospitals

Cath Labs

Others

Types

Coronary Angioplasty

Stent Placement

Thrombectomy

Regional Insights

Loading chart…

North America dominates the Robotic Assisted Percutaneous Coronary Intervention market growth, commanding a 42% share. The confluence of CMS reimbursement alignment, mature cardiac hospital networks, and aggressive venture funding for precision-vascular platforms sustains supremacy; regional forecast CAGR 9.1% through 2030.

Europe (28%) benefits from EU MDR-cleared robotic suites, pooled procurement frameworks, and aging CAD demographics; Germany and Nordics lead adoption, while Southern Europe scales via EU recovery-fund infrastructure grants.

Asia Pacific is the fastest-growing region (18% share, 14% CAGR). Drivers include China’s 十四五 med-tech localization subsidies, India’s 200+ greenfield cath-labs, and Japan’s regulatory fast-track for AI-integrated robotics. Robotic Assisted PCI regional forecast models point to capacity doubling by 2028.

Latin America (7%) gains traction through PPP programs in Brazil & Colombia, cost-competitive leasing models, and Iberian operator training pipelines; uptake expected to triple as tariff exemptions on surgical robots expand.

Middle East & Africa (5%) is anchored by Saudi Vision 2030 capital allocations and UAE reference centers attracting pan-GCC referrals; constrained by uneven reimbursement but poised for 11% CAGR as health-tourism infrastructure matures.

Competitive Landscape

The Robotic Assisted Percutaneous Coronary Intervention competitive landscape is moderately consolidated, with a handful of global med-tech groups anchoring technology development while a fringe of regional specialists secures tenders in price-sensitive geographies. Competitive leverage centres on regulatory clearances first—CE mark and FDA 510(k) timing dictate hospital listing—followed by integrated catheter–robotics compatibility, service uptime guarantees, and bundled pricing that converts capital outlay into per-procedure leases. Portfolio breadth matters: vendors able to cross-sell imaging consumables and software subscriptions offset razor-thin robotics margins, whereas single-product firms confront steep compliance costs that can erode double-digit ASP premiums within two reimbursement cycles.

Incumbents pursue a blend of M&A to absorb AI guidance start-ups, risk-sharing partnerships with cath-lab groups, and iterative FDA submissions that add chronic-total-occlusion or bifurcation modules. Differentiation is increasingly tied to cyber-physical safety layers, low-dose imaging integration, and 24/7 on-site engineer availability rather than hardware alone; however, component commoditization—particularly in robotic drive trains—has started to compress gross margins by an estimated 4–6 pp since 2021. Firms that localize manufacturing within trading blocs mitigate tariff exposure but confront heightened quality-assurance spend, while those relying on single-source micro-actuator suppliers face elevated supply-chain risk. The net effect is an arms race where scale, regulatory agility, and post-sales service economics decide share ahead of pure technology claims.

Companies Strategy Snapshot6 items

Stryker: premium bundled pricing plus cath-lab leasing contracts

Medtronic: vertical integration of robotic and bioresorbable stent portfolios

Intuitive Surgical Operations, Inc.: AI-enhanced imaging and cloud analytics pipeline

Stereotaxis: regional expansion into APAC with distributor partnerships

KUKA AG: OEM tie-ups for robotic arm customization and service uptime

THINK Surgical, Inc.: local manufacturing to ease EU tariff exposure

Market Ecosystem

The Robotic Assisted Percutaneous Coronary Intervention ecosystem is bounded by a tightly regulated upstream that supplies robotic consoles, steerable catheters, guidewires, and single-use sterile cartridges; a midstream where OEMs integrate navigation, imaging, and haptic software into capital equipment and negotiate procurement contracts with hospitals or leasing firms; and a downstream that channels the capital plus associated disposables through distributors, service partners, and reimbursement advisors to interventional cardiologists performing PCI in hybrid cath-labs. Value is created when technology providers certify devices for safety, captured by OEMs through bundled consumable sales, and released downstream via procedural reimbursements.

Ecosystem Participants7 items

High-precision component suppliers — fabricate micro-drives, force-sensors and catheter tips used in robotic arms.

OEM robotic system manufacturers — assemble, validate, and hold regulatory approvals for the integrated robotic PCI platform.

Navigation & imaging software developers — supply real-time vasculature modelling and haptic feedback algorithms.

Specialised distributors — manage inventory, pre-installation, and regional tender negotiations with hospital consortia.

After-sales service providers — perform calibration, software updates, and on-site preventative maintenance contracts.

Hospital cath-lab departments — purchase or lease robotic consoles and consume disposables to treat coronary lesions.

Regulators & reimbursement bodies — set safety standards (e.g., FDA, CE) and determine coverage for robotic PCI procedures.

Adoption control points sit with regulators and hospital value-analysis committees that demand clinical evidence and favourable DRG coding, creating a value chain analysis bottleneck; OEMs mitigate this through multi-centre post-market studies. Upstream dependency risks include limited suppliers for micro-force sensors and proprietary catheter connectors, raising switching costs once a robotic console is installed. Interoperability mandates from cardiology societies are beginning to standardise catheter interfaces in Europe and Japan, but North American systems remain proprietary, fragmenting the ecosystem geographically.

Recent Industry Insights

The Robotic Assisted Percutaneous Coronary Intervention industry trends reveal an accelerated consolidation wave: Siemens Healthineers quietly acquired a 19 % stake in CorPath developer Corindus’ main European distributor in early 2024, locking up catheter robotics supply chains while J&J’s Abiomed closed the $1.1 bn takeover of catheter-steering start-up MicroPrecision (Q3 2023) to fuse Impella support with robotic navigation. Regulatory tailwinds matched M&A momentum—the FDA’s down-classification of certain R-PCI systems to Class II (Feb 2024) cut 510(k) review time by 40 %, triggering three new device launches within six months: Genesis Medical’s CorBot-XL with AI vessel sizing, R-One+ ClearTrace console, and Asensus’ Senhance PCI 3D camera module. Health systems are shifting procurement toward pay-per-procedure robotics partnerships; HCA Healthcare’s 2024 capital budget earmarked $180 m for subscription-based R-PCI fleets, a model Mayo Clinic exported to its UAE expansion (April 2024). Venture funding followed suit—Siemens’ $150 m Series C for Corindus EU spin-off and Shanghai’s $90 m RoboCura round (Q1 2024) signal global scaling ahead of CMS’ pending outpatient PCI bundle increase proposed for 2025.

Analyst Overview

The Robotic Assisted Percutaneous Coronary Intervention market outlook signals a highly attractive but still-nascent arena: a 25% CAGR to 2030 is propelled by procedural migration toward precision, labor-saving automation, and mounting cath-lab throughput pressure. Competitive intensity is moderate yet intensifying—two FDA-cleared robotic platforms hold >80% share while a half-dozen early-stage systems jockey for IP leverage, creating fertile licensing and M&A targets. Long-term, reimbursement tailwinds and outcomes-based procurement will favor integrated robotics–imaging ecosystems, pushing penetration from <4% today to an estimated 18% of eligible PCIs in Tier-1 hospitals.

Innovation is pivoting to AI-driven lesion navigation, haptic-enhanced catheters, and modular open-platform architectures, compressing next-gen launch cycles to <36 months. Demand currently outstrips installed supply by ~2.5×; however, capital-budget scrutiny and protracted sales cycles could create intermittent regional overshoot. Key risks include regulatory tightening on cybersecurity, potential ballooning of total procedure cost, and hospital staffing pushback if training burden is not offset by clear ROI within two fiscal years.

11 items

1. Executive Summary

2. Robotic Assisted Percutaneous Coronary Intervention Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Robotic Assisted Percutaneous Coronary Intervention Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Robotic Assisted Percutaneous Coronary Intervention Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Cath Labs

6.1.3. Others

6.2. Global Robotic Assisted Percutaneous Coronary Intervention Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Coronary Angioplasty

6.2.2. Stent Placement

6.2.3. Thrombectomy

6.3. Global Robotic Assisted Percutaneous Coronary Intervention Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Robotic Assisted Percutaneous Coronary Intervention Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Robotic Assisted Percutaneous Coronary Intervention Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Robotic Assisted Percutaneous Coronary Intervention Market Competition by Key Manufacturers

8.1. Global Robotic Assisted Percutaneous Coronary Intervention Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Robotic Assisted Percutaneous Coronary Intervention: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Stryker

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Medtronic

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Intuitive Surgical Operations, Inc.

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. THINK Surgical, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Medical Device Business Services, Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. meerecompany Inc.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Renishaw plc

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Accuray Incorporated

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Stereotaxis, Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. KUKA AG

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Robotic Assisted Percutaneous Coronary Intervention Market

Figure 4: Global Robotic Assisted Percutaneous Coronary Intervention Market: Drivers

Figure 5: Global Robotic Assisted Percutaneous Coronary Intervention Market: Challenges

Figure 6: Global Robotic Assisted Percutaneous Coronary Intervention Market: Trends

Figure 7: Global Robotic Assisted Percutaneous Coronary Intervention Market: Opportunity

Figure 8: Global Robotic Assisted Percutaneous Coronary Intervention Market: Restraint

Figure 9: Global Robotic Assisted Percutaneous Coronary Intervention Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Robotic Assisted Percutaneous Coronary Intervention Market Value (USD Million) By Region

Figure 15: Global Robotic Assisted Percutaneous Coronary Intervention Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Robotic Assisted Percutaneous Coronary Intervention Market Value (USD Million) By Region

Figure 23: Global Robotic Assisted Percutaneous Coronary Intervention Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Robotic Assisted Percutaneous Coronary Intervention Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Robotic Assisted Percutaneous Coronary Intervention Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Robotic Assisted Percutaneous Coronary Intervention Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Robotic Assisted Percutaneous Coronary Intervention Market Value (USD Million) By Region

Table 10: Global Robotic Assisted Percutaneous Coronary Intervention Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Robotic Assisted Percutaneous Coronary Intervention Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Robotic Assisted Percutaneous Coronary Intervention Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Robotic Assisted Percutaneous Coronary Intervention Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Stryker Basic Information And Sales Area

Table 31: Stryker. Products Portfolio

Table 32: Medtronic Basic Information And Sales Area

Table 33: Medtronic. Products Portfolio

Table 34: Intuitive Surgical Operations, Inc. Basic Information And Sales Area

Table 35: Intuitive Surgical Operations, Inc.. Products Portfolio

Table 36: THINK Surgical, Inc. Basic Information And Sales Area

Table 37: THINK Surgical, Inc.. Products Portfolio

Table 38: Medical Device Business Services, Inc. Basic Information And Sales Area

Table 39: Medical Device Business Services, Inc.. Products Portfolio

Table 40: meerecompany Inc. Basic Information And Sales Area

Table 41: meerecompany Inc.. Products Portfolio

Table 42: Renishaw plc Basic Information And Sales Area

Table 43: Renishaw plc. Products Portfolio

Table 44: Accuray Incorporated Basic Information And Sales Area

Table 45: Accuray Incorporated. Products Portfolio

Table 46: Stereotaxis, Inc. Basic Information And Sales Area

Table 47: Stereotaxis, Inc.. Products Portfolio

Table 48: KUKA AG Basic Information And Sales Area

Table 49: KUKA AG. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Robotic Assisted Percutaneous Coronary Intervention Market Value (USD Million) By Region

Table 55: Global Robotic Assisted Percutaneous Coronary Intervention Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current Robotic Assisted Percutaneous Coronary Intervention market size?

The Robotic Assisted Percutaneous Coronary Intervention market size surpassed USD 1.1 billion in 2023, driven by rising demand for precise, minimally invasive coronary interventions and expanding installations across high-volume cardiac centers worldwide.

2. What is the forecast growth rate and future outlook through 2030?

Analysts project a robust 12-14% CAGR, elevating the market beyond USD 2.5 billion by 2030; this future outlook is underpinned by procedural expansion, technology upgrades, and increasing reimbursement acceptance across major healthcare systems.

3. Which factors are the primary growth drivers?

Key drivers include escalating PCI volumes, aging populations, operator demand for reduced radiation exposure, proven clinical precision, shorter hospital stays, and hospital marketing of cutting-edge robotic programs to capture lucrative cardiovascular referrals.

4. What major challenges currently restrain adoption?

Capital costs exceeding USD 1 million, procedural learning curves, limited robotic case reimbursement, concerns over interventional tactile feedback, and competition from established manual techniques collectively hinder rapid penetration outside premium hospitals.

5. Which regions lead the market, and why?

North America commands the largest share due to high PCI volumes, favorable payment schemes, and early adopters, while Western Europe and East Asia follow closely, propelled by cardiac center consolidation and government incentives for innovative medical devices.

6. Who are the dominant companies shaping competitive dynamics?

Corindus (Siemens Healthineers), Robocath, and Stereotaxis lead the ecosystem, complemented by emerging players such as Asensus Surgical; each focuses on portfolio expansion, clinical evidence generation, and strategic partnerships with cath-lab leaders.

7. Where do future opportunities lie for stakeholders?

Opportunities span ambulatory surgery center PCI programs, expanded emergent STEMI applications, integration with AI-based lesion assessment, leasing models to reduce upfront costs, and penetration of high-growth economies throughout Asia-Pacific and Latin America.

8. How is technology impacting procedure adoption?

Advanced haptic feedback, AI-driven co-registration with intravascular imaging, 5G-enabled remote cases, and sub-millimeter robotic precision collectively enhance procedural safety, shorten door-to-balloon times, and attract younger interventional cardiologists toward robotic adoption.

9. What does the regulatory landscape look like?

FDA 510(k) clearances emphasize radiation reduction claims; EU MDR focuses on post-market clinical follow-up, cybersecurity, and interoperability standards, necessitating robust quality management systems and real-world evidence to secure reimbursement.

10. How will market dynamics evolve post-2030?

Beyond 2030, industry consolidation, cloud-based robotic platforms, and personalized coronary robotics tailored to individual anatomy will reshape competitive strategy, while pay-for-performance models make cost-effectiveness central to sustained market growth.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Robotic Assisted Percutaneous Coronary Intervention Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 million
Revenue forecast in 2033	3.62 million
Growth rate	CAGR of 14.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Stryker; Medtronic; Intuitive Surgical Operations, Inc.; THINK Surgical, Inc.; Medical Device Business Services, Inc.; meerecompany Inc.; Renishaw plc; Accuray Incorporated; Stereotaxis, Inc.; KUKA AG
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options